The therapeutic response to chemically_synthesized la-hydroxycholecalciferol (la-OH-D,) was studied in three patients with autosomal recessive vitamin D dependency (ARVDD). The daily maintenance dose for vitamin D,, to prevent signs of vitamin D deficiency in these patients, was 40-54.5 fig/kg, or about 100 times normal (Table 1) . Withdrawal of maintenance therapy with vitamin D, resulted in the ultimate reappearance of the vitamin D depletion syndrome in patients I and 2 ( Figs. 1 and 2) . The third patient presented with the deficiency syndrome despite adequate vitamin D nutrition and was recognized to have ARVDD.
Extract
The therapeutic response to chemically_synthesized la-hydroxycholecalciferol (la-OH-D,) was studied in three patients with autosomal recessive vitamin D dependency (ARVDD). The daily maintenance dose for vitamin D,, to prevent signs of vitamin D deficiency in these patients, was 40-54.5 fig/kg, or about 100 times normal ( Table 1) . Withdrawal of maintenance therapy with vitamin D, resulted in the ultimate reappearance of the vitamin D depletion syndrome in patients I and 2 ( Figs. 1 and 2 ). The third patient presented with the deficiency syndrome despite adequate vitamin D nutrition and was recognized to have ARVDD.
Treatment with la-OH-D, by mouth in all three patients at dose levels of 1-3 pg/24 hr (8@100 ng/kg) corrected hypocalcemia and suppressed parathyroid hormone-dependent renal loss of amino acids (Figs. 1,2, and 4). Rickets healed in 7-9 weeks on la-OH-D, alone ( Fig. 3 ) The therapeutic response was rapid. It was usually seen first in the rise of serum calcium (Figs. 5 and 6). Withdrawal of la-OH-D, was followed first by a fall of serum phosphorus, then by a fall in serum calcium; the latter occurred within about 2 weeks of withdrawal.
Because the synthesis of la-OH-D, is simpler than for la,25-dihydroxycholecalciferol and because the former is an effective therapeutic analog of vitamin D hormone, we believe these studies in ARVDD reveal la-OH-D, to be the agent of choice for treatment of this and analogous diseases.
Speculation
Vitamin D dependency or pseudodeficiency rickets is believed to be an inborn error of vitamin D hormone biosynthesis. The putative abnormal enzyme is 25-hydroxycholecalciferol 1-hydroxylase in the recessively inherited trait. Consequently, this experiment of nature offers a special opportunity to examine the requirement in human subjects, for la-hydroxyvitamin D, metabolites.
Patients with ARVDD (14, 18, 36) develop signs of severe postnatal vitamin D deficiency, despite a nutritional intake of vitamin D, or vitamin D, (40) that would prevent rickets in normal subjects; hence the term pseudodeficiency preferred by some investigators (34) . Persistent hypocalcemia appearing soon after birth is accompanied by an excess of circulating parathyroid hormone (I) which in turn is associated with hyperphosphaturia and hyperaminoaciduria (1, 37) . Elevated serum alkaline phosphatase activity, severe rachitic bone lesions, and enamel hypoplasia affecting teeth that form postnatally complete the clinical syndrome ( I , l I, 14, 18, 34, 36) . Maintenance treatment with vitamin D, only at levels about 100 times the normal requirement fully reverses the manifestations of deficiency hence the term vitamin D dependency (18, 36) .
The origin of the disturbed physiology in ARVDD lies in a selective disturbance of calcium absorption by intestine (18) . A defect either in the biosynthesis of the active hormone form of vitamin D or in the ability of target organ(s) to respond to vitamin D hormone has been proposed (36) to explain the dependency on vitamin D,, D,, or 25-OH-D, of patients with ARVDD. ARVDD patients respond to microgram doses of chemically synthesized la,25-dihydroxycholecalciferol (Ia,25-(OH),-D,) (12) . This finding has been corroborated by several investigators (3). It is surmised that a missing form of vitamin D hormone had been supplied and that ARVDD is likely to be an inborn error of vitamin D hormone biosynthesis, probably at the I-hydroxylation step (12) ; this hypothesis is in keeping with the autosomal recessive inheritance of the disease.
Treatment of ARVDD with a "surrogate" vitamin D hormone, such as la-hydroxycholecalciferol (la-OH-D,) (22, 24) , would be advantageous. Crystalline la-OH-D, is more easily synthesized than la,25-(OH),-D,, and the former can be effectively administered by mouth. Moreover, ARVDD is an experiment of nature which provides an admirable opportunity to observe the effect of la-OH-D, in man. The present report reveals the therapeutic value of crystalline la-OH-D, in ARVDD and its preference over a similar synthetic analog of vitamin D, namely dihydrotachysterol (DHTz).
PATIENTS
Three patients, between the ages of 17 months and 9.5 years, were investigated. A case study for patient 1 has been previously reported in detail (I); she is the second-born of dizygotic twins and exhibited intrauterine growth retardation at birth. Patient 2 was diagnosed at 18 months of age and has been followed by us since 1965. Patient 3 presented at 17 months of age during the course of the present investigation at which time the diagnosis of vitamin D dependency was made. She was enrolled in the study before maintenance treatment was prescribed.
Each patient has shown the characterictic clinical and biochemical features of ARVDD in the absence of adequate treatment with vitamin D. Patient 1 inherited the trait in autosomal recessive fashion (I). Inheritance of the trait in patients 2 and 3 who are isolated probands cannot be proven through heterozygote detection by available clinical methods(1).
PROTOCOLS FOR ASSESSMENT OF 10-OH-D, EFFICACY(41)
Maintenance Requirements for Vitamin D,, The requirements for vitamin D,, in patients I and 2, to maintain normal serum calcium levels and prevent rickets have been observed over many years and range between 0.6 mg and 1.25 mg/24 hr (42) (41 and 55 pg/kg), and are about 100 times normal. The vitamin D, requirement for patient 3 has yet to be finalized but will be of similar order.
Evaluation of Response to la-OH-D, . The effect of la-OH-D, was studied de novo in patient 3. In patients 1 and 2 it was necessary to discontinue maintenance therapy with vitamin D, in order to determine their requirement for la-OH-D, They were observed carefully by home visiting until evidence of modest hypocalcemia and reappearance of the parathyroid hormonedependent mainifestations was apparent. Linear growth rate and bone mineralization were also monitored. The response to la-OH-D, was then observed in hospital while the patients received normal diets. The la-OH-D, was given by mouth at 9 A M in doses of 1-3 pg/24 hr. The response was evaluated by serial, daily measurements of total calcium, inorganic phosphorus, and alkaline phosphatase activity in serum. Urinary amino acids were monitored at less frequent intervals. Bone mineralization was evaluated by periodic x-ray examination. It was not possible to perform external balance studies for calcium and phosphorus. Patients 1 and 3 received one course each of la-OH-D,; patient 2 was given the substance on three successive occasions at doses of 1 as a solution containing 2 pg/ml dissolved in propylene glycol. The stock solution was stored at -20' in the dark under nitrogen. The substance was chemically synthesized in the Department of Biochemistry, College of Agriculture and Life Sciences, University of Wisconsin, Madison. la,25-(OH),-D, and 25-OH-D, were obtained from the same source and stored in similar fashion.
Dihydrotachysterol was obtained in liquid form (Hytakerol) from Winthrop Laboratories, Aurora, Ontario. Patient 2 was given 5 pg/24 hr by mouth for the first 15 weeks after maintenance therapy with vitamin D, was terminated.
Laboratory Methods. Blood was drawn from the antecubital vein at a constant time of day in each patient and allowed to clot. Serum was collected and total calcium and inorganic phosphorus were determined by the methods of Gitelman (15) and Kraml (27) , respectively, adapted for the Technicon AutoAnalyzer. Serum total alkaline phosphatase activity in patients I and 2 was determined by a modification of the ,method of Bessey et al. (16) ; the King-Armstrong method (25) was used for patient 3. Urine amino acids were determined by, partition chromatography in two dimensions by the method of Dent (10) and measured semiquantitatively as described previously (13, 16) . Serum 25-hydroxyvitamin D was measured by the competitive.protein-binding assay of Haddad and Chyu (17) .
ANALYSIS OF DATA
Time courses for the biochemical responses were plotted in conventional fashion. The cumulative sum (cusum) method of analysis (23) was then used to study the clinical response to la-OH-D,. The cusum values were derived by subtracting a selected baseline value from the serial daily values for which the pretreatment baseline is the mean of the last three serial determinations before administration of la-OH-D,, the baseline for the withdrawal response is the mean of the values obtained on the last 3 days of treatment with la-OH-D,. The A values (observed value minus baseline) during the particular study were then summed cumulatively and plotted as a time course according to their sign (upward for positive values, downward for negative). The cusum method permits significant trends in response to a therapeutic agent to be distinguished amidst the customary analytic noise in clinical studies (23 for a number of years (Table I ). The time courses for reappearance Therapeutic Agents. Crystalline la-OH-D, was given by mouth of the ARVDD phenotype are shown in Figures 1 and 2 . The first presented with hypocalcemia and hypophosphatemia. Bone Response. Serum alkaline phosphatase activity rose in patients 1 and 2 beginning about 8 weeks after vitamin D, treatment was stopped. Over 80% of the augmented activity was heat labile, indicating bone as its major source (33) . Alkaline phosphatase activity in serum plateaued at a level two-to threefold above that present during maintenance therapy with vitamin D,, Radiographic examinations of long bones and skull revealed mild progressive rachitic changes emerging after withdrawal of antirachitic treatment. The process was most severe inpatient 2 (Fig.3A) . Patient 3, who had not previously received maintenance therapy, presented with florid rickets (Fig. 3C ) and elevated plasma alkaline phosphatase activity.
Linear Growth. Withdrawal of maintenance vitamin D, therapy was followed by slowing of linear growth in patient 2: the actual rate was 10% of that expected from her normal percentile during D ) showing healing of rickets in 7 weeks and 9 weeks, respectively, during administration of la-hydroxyvitamin D, (2-3 /*g/24 hr by mouth). (Table I) . Unfortunately, vitamin D, had been given before diagnosis (375 pg/24 hr for 5 weeks). Two months later, after treatment with la-OH-D, alone, the serum 25-OH-D level in this patient was still elevated (50 ng/ml) (Fig. 4) .
Patient 3 had an elevated initial concentration of 25-OH-vitamin D in serum

RESPONSE TO CRYSTALLINE la-OH-D,
Total Calcium and Inorganic Phosphorus in Serum. l a-OH-D, was administered by mouth to each patient in small doses (3 pg or less daily) (Table I ). A prompt response followed; time courses are shown in Figures 1, 2 , and 4.
Cusum plots (Figures 5 and 6 ) reveal that the serum calcium rises within 48 hr of la-OH-D, treatment, whereas serum inorganic phosphorus rises slightly later. The calcium x phosphorus hypocalcemic, hypophosphatemic stage, first at a dose level of 2 wg/24 hr and then at 3 pg/24 hr. With each trial of l a -O H -D , , the serum calcium rose first, anticipating the rise in serum phosphorus by at least 1 day.
Patient 3, who presented with florid rickets (Fig. 3C ) experienced an unusual serum response to la-OH-D, (Fig. 4) . Serum calcium rose immediately and reached the normal range within 1 week. However, serum inorganic phosphorus fell initially, rising only after the 4th week of treatment. The initial calcium x phosphorus product in serum rose to exceed 30 but during the subsequent 3 weeks, the average value was below 30. Movement of mineral into bone may explain these findings, because radiographic evidence of remineralization appeared within 2 weeks of la-OH-D, therapy. product in serum subsequently increases to a value above 30.
BONE RESPONSE
On three occasions la-OH-D, was given to patient 2; once at a dose level of 1 pg/24 hr in the normocalcemia, hypophosphaAlkaline phosphatase activity in serum fell immediately after temic state of the vitamin D depletion syndrome; and twice in the initiation of la-OH-D, treatment, and radiographic examination la-HYDROXYVITAMIN D, RESPONSE IN VITAMIN D DEPENDENCY of bones showed repair of the rachitic lesions in all three patients.
LINEAR GROWTH RATE Rickets in patient 2 was healed with la-OH-D3 treatment alone in 7 weeks (Fig. 3B) . Florid rickets was healed in patient 3 in 9 weeks on la-OH-D, (Fig. 30) .
During the course of treatment with la-OH-D,, hypeiaminoaciduria subsided, in keeping with repair of the hypocalcemia and suppression of endogenous hyperparathyroidism (1, 13, 16, 37) . (Figs. 1 and 2) . Acceleration of the linear growth rate was observed in patient 3, to 160% of her normal percentile during the 9-week long third course of la-OH-D, (3 pg/24 hr) treatment. Accelerated growth continued when maintenance with vitamin D, was reinstituted.
RESPONSE T O WITHDRAWAL O F lo-OH-D,
The la-OH-D, therapy was intermitted in patients 1 and 2. Serum calcium remained elevated in the first patient for 18 days, and then declined; serum phosphorus fell within the first few days after withdrawal of la-OH-D3 (Figs. 2, 5, and 6 ). In patient 2, la-OH-D, was stopped after 2-week courses at dose levels of I pg/24 hr and 2 pg/24 hr, respectively. On both occasions, the vitamin D depletion syndrome reappeared. (12) and its first hydroxylation product, 25-OH-vitamin (4, 5, 12) place the putative enzymatic defect, in the majority of patients studied so far, at the level of 25-hydroxycholecalciferol I-hydroxylase in kidney (12) .
The possibility that other patients with the vitamin D dependency syndrome will have an attenuated response of target tissues to normal amounts of vitamin D hormone, or will have a block in hormone biosynthesis at another level, or of a different degree of "completeness," is entirely possible. It is the nature of recessive mendelian traits in man to exhibit genetic heterogeneity (9, 28) . Differcnccs in the maintenance requirement for 25-OH-D, and vitamin D, among patients with apparent vitamin D dependency have already been reported (35, 38) . A description of the cellular events which determine the vitamin D dependent trait might be obtained in more detail through investigation of a promising animal model in swine (19, 30) .
Several investigators (1 1, 18) have reported that "antirachitic activity" in serum, as determined by various bioassays, is at least normal, or higher than normal, in vitamin D dependency. However, this type of assay often does not discriminate between vitamin D and its more active polar metabolites. In the study of (17) , to be significantly elevated in our patients. However, this finding does not tell us whether the level of 25-OH-D, in the cytosol of target cells is elevated. Nonetheless, normal calcium metabolism was not sustained under the observed conditions implying that adequate specific replacement of l ahydroxylated vitamin D is necessary in ARVDD. The parathyroid hormone-dependent disturbance of tubular reabsorption affecting amino acids and phosphorus is not prevented by the elevated levels of 25-OH-D, in this "calciopenic" form of rickets (37) .
Whether the raised serum 25-OH-vitamin D level represents metabolite accumulation in a blocked biosynthetic pathway or merely a persistent increase because of previous maintenance therapy at high dose levels is not clear from our study. Serum 25-OH-D, does not accumulate in chronic renal failure (2, 29) or after nephrectomy (31), when there is interference with renal I-hydroxylase activity, except when large doses of vitamin D are administered for a long time (39) .
DHT, has a hydroxyl group in position 3 rotated 180' so that the hydroxyl occupies a position analogous to position I. Nonetheless, DHT, appears not to be effective in A R V D D in the low microgram dose range, and our limited observations suggest that DHT, is not equivalent to the la-hydroxy metabolites of vitamin D in man, corroborating the earlier findings of Harrison and Harrison (20) in the rat.
The response of la-OH-D,, in ARVDD is equivalent to the earlier reported effect of la,25-(OH),-D, (12) . These observations offer a more direct evaluation of the efficacy of la-OH-D, than earlier studies with the agent in patients with malabsorption syndromes (7, 32) and renal failure (8) . It is not yet certain whether responsiveness to la-OH-D, is dependent on further 25-hydroxylation, but observations in virro (26) suggest this is the case. Because dependence on vitamin D hormone is not likely to be outgrown in ARVDD, we anticipate a preference for la-OH-D, over vitamin D, during long term treatment. The response to la-OH-D, in ARVDD requires only a matter of a day or two; by contrast, weeks are required to achieve a stable treatment response with vitamin D, . We have also shown that the vitamin D depletion syndrome appears within a few days after withdrawal of l a -O H -D, in ARVDD, an advantageous feature for the avoidance of vitamin D toxicity.
The apparent normal maintenance dose for la-OH-D, is on the order of 80 ng/kg in later childhood and early puberty.
S U M M A R Y
Vitam~n D dependency (pseudodeficiency rickets), a postnatal autosomal recessive condition in which calcium absorption is compromised and with attendant manifestations of secondary hyperparathyroidism, is believed to be the result of deficient I-hydroxylation of 25-hydroxyvitamin D. Therefore, the therapeutic effect of synthetic crystalline la-hydroxyvitamin D, was examined in three patients who fully expressed the syndrome, despite serum 25-hydroxyvitamin D levels elevated two-to sevenfold above normal. Whereas pharmacologic doses (40-54.5 ~g / kg124 hr) of vitamin D, were required to prevent manifestations of vitamin D deficiency in these patients, the effective maintenance dose of la-OH-D, was only 80-100 ng/kg/24 hr. The latter substance is effective by mouth within 1 or 2 days and its biologic effect is short-lived (days only). These studies yield a first approximation of the requirement for la-OH-D, and reveal that it may be the agent of choice for management of this and analogous diseases.
